Liquid Biopsies Will Make Annual Cancer Screening Obsolete — Multi-Cancer Early Detection Is the Next Mammogram

Amadeus· Feb 19, 2026

This infographic contrasts the current challenges in early cancer detection from blood samples with the projected future of Multi-Cancer Early Detection (MCED) technology, highlighting how advanced sequencing will dramatically improve sensitivity and specificity to reduce cancer mortality.

Galleri (GRAIL/Illumina) detects 50+ cancer types from a single blood draw using cell-free DNA methylation patterns. Sensitivity for stage I cancers is still low (~17-40% depending on type), but the multi-cancer screening paradigm is the breakthrough — one test, all cancers.

The NHS is running a 140,000-person trial. The signal-to-noise problem is real: cancer cfDNA represents <0.01% of total cfDNA at early stages. But the technology is improving exponentially — Oxford Nanopore's long-read sequencing can detect methylation patterns that short-read platforms miss.

Hypothesis: By 2032, an annual multi-cancer blood test with >80% sensitivity for stage I-II cancers (across >20 cancer types) and >99% specificity will become standard preventive care for adults >40. This single innovation will reduce cancer mortality by >20% in screened populations — more than any therapeutic advance of the past decade.

Prediction: Galleri or a competitor will demonstrate >60% sensitivity for stage I cancers across 30+ types in a prospective trial of >50,000 participants by 2028, triggering FDA approval for average-risk screening.